Search Result

Isoforms Recommended:	CDK7

Results for "

CDK7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (12) ATM/ATR (1) Autophagy (1) Casein Kinase (2) CDK (62) ERK (1) GSK-3 (1) HDAC (1) HIV (2) HSV (2) Molecular Glues (2) PKC (1) PROTACs (1) Small Interfering RNA (siRNA) (3) STAT (1)
By Research Areas:	Cancer (60) Infection (2) Metabolic Disease (1) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS02395

CDK7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK7 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK7 Human Pre-designed siRNA Set A CDK7 Human Pre-designed siRNA Set A

HY-RS02396

Cdk7 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk7 Mouse Pre-designed siRNA Set A Cdk7 Mouse Pre-designed siRNA Set A

HY-RS02397

Cdk7 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk7 Rat Pre-designed siRNA Set A Cdk7 Rat Pre-designed siRNA Set A

HY-139986

CDK7-IN-5

CDK Cancer

CDK7-IN-5 is a CDK7 inhibitor with an IC₅₀ value <100 nM. CDK7-IN-5 has anticancer effects. (WO2015154022A1 (Compound 104)) .

CDK7-IN-5	CDK	Cancer
CDK7-IN-5 is a *CDK7* inhibitor with an IC₅₀ value <100 nM. CDK7-IN-5 has anticancer effects. (WO2015154022A1 (Compound 104)) .

HY-145655

CDK7-IN-11	CDK	Cancer
CDK7-IN-11 is an orally active *CDK7* inhibitor. CDK7-IN-11 exhibits high CDK7 inhibitory activity with IC₅₀ value of 4.2 nM. CDK7-IN-11 can be effectively used for the research of diseases associated with CDK7 .

HY-147597

CDK7-IN-13	CDK	Cancer
CDK7-IN-13 is a potent inhibitor of *CDK7. CDK7-IN-13 is a pyrimidinyl derivative compound. CDK7*-IN-13 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1) .

HY-147600

CDK7-IN-15	CDK	Cancer
CDK7-IN-15 is a potent inhibitor of *CDK7. CDK7-IN-15 is a pyrimidinyl derivative compound. CDK7*-IN-15 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 8) .

HY-147602

CDK7-IN-17	CDK	Cancer
CDK7-IN-17 is a potent inhibitor of *CDK7. CDK7-IN-17 is a pyrimidinyl derivative compound. CDK7*-IN-17 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1) .

HY-147603

CDK7-IN-18	CDK	Cancer
CDK7-IN-18 is a potent inhibitor of *CDK7. CDK7-IN-18 is a pyrimidinyl derivative compound. CDK7*-IN-18 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 15) .

HY-147598

CDK7-IN-14	CDK	Cancer
CDK7-IN-14 is a potent inhibitor of *CDK7. CDK7-IN-14 is a pyrimidinyl derivative compound. CDK7*-IN-14 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 3) .

HY-144175

CDK7-IN-12	CDK	Cancer
CDK7-IN-12 is a potent inhibitor of *CDK7. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit malignant tumor proliferation in vitro and in vivo. CDK7*-IN-12 has the potential for the research of cancer disease (extracted from patent WO2021249417A1, compound 43) .

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible *CDK7* (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-143586

CDK7-IN-8

CDK Cancer

CDK7-IN-8 is a potent CDK7 inhibitor with IC₅₀ of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models .
HY-153950

CDK7-IN-22

CDK Cancer

CDK7-IN-22 (compound 101) is an CDK7 inhibitor with antitumor activity. CDK7-IN-22 shows selectivity on CDK7 .
HY-136711

CDK7-IN-2 hydrochloride hydrate

CDK Cancer

CDK7-IN-2 hydrochloride hydrate (Example 6) is a potent and selective CDK7 inhibitor. CDK7-IN-2 has potent anti-cancer activity .

CDK7-IN-8	CDK	Cancer
CDK7-IN-8 is a potent *CDK7* inhibitor with IC₅₀ of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models .

CDK7-IN-22	CDK	Cancer
CDK7-IN-22 (compound 101) is an *CDK7* inhibitor with antitumor activity. CDK7-IN-22 shows selectivity on CDK7 .

CDK7-IN-2 hydrochloride hydrate	CDK	Cancer
CDK7-IN-2 hydrochloride hydrate (Example 6) is a potent and selective *CDK7* inhibitor. CDK7-IN-2 has potent anti-cancer activity .

HY-145394

CDK7-IN-6	CDK	Cancer
CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC₅₀≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer .

HY-153278

CDK7-IN-21

CDK Cancer

CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor .

CDK7-IN-21	CDK	Cancer
CDK7-IN-21 (compound A22) is a potent *CDK7* inhibitor .

HY-145424

CDK7-IN-10	CDK	Others
CDK7-IN-10 is a *CDK7* inhibitor with an IC₅₀ of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell apoptosis .

HY-139342

CDK7-IN-4	CDK	Cancer
CDK7-IN-4 (compound I) is a potent *CDK7* (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner .

HY-143587

CDK7-IN-2	CDK	Cancer
CDK7-IN-2 is a potent inhibitor of *CDK7. CDK7* is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1) .

HY-162416

CDK7-IN-27

CDK Cancer

CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with K_i of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase .
HY-P2559

CDK7/9 tide

CDK Cancer

CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

CDK7-IN-27	CDK	Cancer
CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with K_i of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase .

CDK7/9 tide	CDK	Cancer
CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

HY-46568

CDK7/12-IN-1	CDK	Cancer
CDK7/12-IN-1 is a selective *CDK7/12* inhibitor with IC₅₀s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth .

HY-145408

CDK7/9-IN-1	CDK	Cancer
CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 (CDK7/9) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC₅₀s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibits CDK9 with an IC₅₀ of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research of cancer .

HY-156705

CDK7-IN-25

CDK Cancer

CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC₅₀<1nM) that can be used in cancer research .
HY-145402

CDK7-IN-7

CDK Cancer

CDK7-IN-7 is a potent and selective CDK7 kinase inhibitor with an IC₅₀ of <50 nM (Patent CN112661745A, compound T-01) .

CDK7-IN-25	CDK	Cancer
CDK7-IN-25 (CY-16-1) is a *CDK-7* inhibitor (IC₅₀<1nM) that can be used in cancer research .

CDK7-IN-7	CDK	Cancer
CDK7-IN-7 is a potent and selective CDK7 kinase inhibitor with an IC₅₀ of <50 nM (Patent CN112661745A, compound T-01) .

HY-147601

CDK7-IN-16	CDK	Cancer
CDK7-IN-16 (compound 9) is a potent *CDK 7* inhibitor with an IC₅₀ range of 1 ~ 10 nM. CDK7-IN-16 can be used for researching anticancer, especially the cancer with transcriptional dysregulation .

HY-157210

CDK7-IN-26	CDK	Cancer
CDK7-IN-26 (compound 36) is an orally active *CDK7* inhibitor (IC₅₀: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC₅₀ of 0.15 μM .

HY-138293

SY-5609 1 Publications Verification CDK7-IN-3	CDK Apoptosis	Cancer
SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent *CDK7* inhibitor with a K_D of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (K_i=2600 nM), CDK9 (K_i=960 nM), CDK12 (K_i=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .

HY-156444

*HDAC1/CDK7-IN-1*	HDAC CDK Apoptosis	Cancer
HDAC1/CDK7-IN-1 (compound 8e) is a dual *CDK7* and HDAC1 inhibitor with IC₅₀s of 893 nM and 248 nM, respectively. HDAC1/CDK7-IN-1 inhibits the growth cells of MDA-MB-231, MCF-7, A549, and HCT-116 cancer cells. HDAC1/CDK7-IN-1 induces cell cycle arrest and apoptosis in HCT-116 cells, as well as hindered the migration of HCT-116 cells .

HY-101257B

YKL-5-124 TFA 5 Publications Verification	CDK	Cancer
YKL-5-124 TFA is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-80013B

(E/Z)-THZ1 dihydrochloride

CDK Cancer

(E/Z)-THZ1 dihydrochloride is a selective inhibitor of CDK7 with an IC₅₀ of 3.2 nM. (E/Z)-THZ1 dihydrochloride has antiproliferative effect .

(E/Z)-THZ1 dihydrochloride	CDK	Cancer
(E/Z)-THZ1 dihydrochloride is a selective inhibitor of CDK7 with an IC₅₀ of 3.2 nM. (E/Z)-THZ1 dihydrochloride has antiproliferative effect .

HY-116871

YKL-1-116	CDK	Cancer
YKL-1-116 is a selective and covalent inhibitor of *Cdk7. YKL-1-116 does not target Cdk9, Cdk12, or Cdk13. YKL-1-116 is more potent than THZ1 (HY-80013) toward both Cdk7* ^WT and Cdk7 ^as, although Cdk7 ^as is relatively resistant to this compound as well .

HY-13266A

BS-181 hydrochloride 4 Publications Verification	CDK	Cancer
BS-181 hydrochloride is a highly selective *CDK7* inhibitor with IC₅₀ of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

HY-128867

bio-THZ1

CDK Cancer

bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7. THZ1 is a selective and potent covalent CDK7 inhibitor with an IC₅₀ of 3.2 nM .

bio-THZ1	CDK	Cancer
bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7. THZ1 is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM .

HY-19988

THZ1-R 3 Publications Verification	CDK	Cancer
THZ1-R is a non-cysteine reactive analog of THZ1 which displays diminished activity for *CDK7* inhibition. THZ1-R binds to *CDK7* with a K_d of 142 nM.

HY-101257

YKL-5-124 5 Publications Verification
YKL-5-124 is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-12280

THZ2

2 Publications Verification

CDK Cancer

THZ2 is a potent and selective CDK7 inhibitor with an IC₅₀ of 13.9 nM.

THZ2 2 Publications Verification	CDK	Cancer
THZ2 is a potent and selective *CDK7* inhibitor with an IC₅₀ of 13.9 nM.

HY-155787

SHR5428	CDK	Cancer
SHR5428 is a potent, orally active, selective and noncovalent inhibitor of *CDK7* with highly potent CDK7 enzymatic activity (IC₅₀=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC₅₀=6.6 nM) .

HY-145389

SZ-015268	CDK	Cancer
SZ-015268 is a *CDK7* inhibitor with an IC₅₀ of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC₅₀s of 33, 80.56, 12.53, and 61.55 nM, respectively .

HY-123955

Casein Kinase inhibitor A86	Casein Kinase CDK Apoptosis	Cancer
Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .

HY-139011

IV-361

CDK Cancer

IV-361 is an orally active and selective CDK7 inhibitor (K_i≤50 nM). IV-361 has anti-cancer activity (US20190256531A1) .

IV-361	CDK	Cancer
IV-361 is an orally active and selective *CDK7* inhibitor (K_i≤50 nM). IV-361 has anti-cancer activity (US20190256531A1) .

HY-12293

LY2857785 4 Publications Verification	CDK Apoptosis	Cancer
LY2857785 is a type I reversible and competitive ATP kinase inhibitor against *CDK9* (IC₅₀ 11 nM) and other transcription kinases *CDK8* (IC₅₀ 16 nM), and *CDK7* (IC₅₀ 246 nM).

HY-13914

Roniciclib

BAY 1000394
CDK Cancer

Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

Roniciclib BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase *(CDK)* inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-80013

THZ1 Maximum Cited Publications 73 Publications Verification	CDK	Cancer
THZ1 is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 also inhibits the closely related kinases *CDK12* and *CDK13* and downregulates MYC expression .

HY-80013A

THZ1 Hydrochloride Maximum Cited Publications 73 Publications Verification	CDK	Cancer
THZ1 Hydrochloride is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases *CDK12* and *CDK13* and downregulates MYC expression .

HY-103712A

Samuraciclib hydrochloride 5 Publications Verification CT7001 hydrochloride; ICEC0942 hydrochloride	CDK Apoptosis	Cancer
Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .

HY-103712B

Samuraciclib hydrochloride hydrate 5 Publications Verification CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-103712

Samuraciclib CT7001; ICEC0942	CDK Apoptosis	Cancer
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects .

HY-103712C

Samuraciclib hydrochloride hydrate 5 Publications Verification CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

Cat. No.	Product Name	Target	Research Area

HY-P2559

CDK7/9 tide

CDK Cancer

CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

HY-P1933

[pSer2, pSer5, pSer7]-CTD	Peptides	Cancer
[pSer2, pSer5, pSer7]-CTD, a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .

HY-P1933A

[pSer2, pSer5, pSer7]-CTD TFA	CDK	Cancer
[pSer2, pSer5, pSer7]-CTD (TFA), a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 7 (CDK7)

Species:	Human (3)
Tag:	His (2) Tag Free (1) GST (1) Flag (1)
Source:	Sf9 insect cells (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P701371

	CDK7-CCNH-MNAT1 Protein, Human (Sf9) CDK7; CCNH; MNAT1; Cyclin-dependent kinase 7; 39 kDa protein kinase; p39 Mo15; CDK-activating kinase 1; Cell division protein kinase 7; Serine/threonine-protein kinase 1; TFIIH basal transcription factor complex kinase subunit; Cyclin-H; MO15-associated protein; p34; p37; CDK-activating kinase assembly factor MAT1; CDK7/cyclin-H assembly factor; Cyclin-G1-interacting protein; Menage a trois; RING finger protein 66; RING finger protein MAT1; p35; p36	Human	Sf9 insect cells
	Together with its regulatory partners CCNH and MNAT1, CDK7 functions as an important serine/threonine kinase in cell cycle regulation and RNA polymerase II-mediated transcription. As the catalytic subunit of the CDK-activated kinase (CAK) complex, CDK7 plays a key role in activating CDK1/cyclin-B and CDK2/cyclin during cell cycle transitions. CDK7-CCNH-MNAT1 Protein, Human (Sf9) is the recombinant human-derived CDK7-CCNH-MNAT1 protein, expressed by Sf9 insect cells , with tag free.

HY-P702688

	CDK7-CCNH-MNAT1 Protein, Human (sf9, GST, His, Flag) CDK7; cyclin-dependent kinase 7; cyclin dependent kinase 7 (homolog of Xenopus MO15 CDK activating kinase) , cyclin dependent kinase 7 (MO15 homolog, Xenopus laevis, CDK activating kinase); CAK; CAK1; CDKN7; MO15; STK1; p39 Mo15; protein kinase; 39 KDa protein kinase; kinase subunit of CAK; CDK-activating kinase 1; serine/threonine kinase stk1; cell division protein kinase 7; serine/threonine protein kinase 1; serine/threonine-protein kinase 1; serine/threonine protein kinase MO15	Human	Sf9 insect cells

HY-P75361

	CDK7&CCNH&MNAT1 Protein, Human (sf9, His) CAK1 Protein; CDKN7 Protein; HCAK Protein; MO15 Protein; p39MO15 Protein; STK1 Protein	Human	Sf9 insect cells
	CDK7, along with regulatory partners CCNH and MNAT1, operates as a crucial serine/threonine kinase in cell cycle regulation and RNA polymerase II-mediated transcription. As the catalytic subunit of the CDK-activating kinase (CAK) complex, CDK7 plays a pivotal role in activating CDK1/cyclin-B and CDK2/cyclins during cell cycle transitions. It phosphorylates key targets, including SPT5/SUPT5H and POLR2A. CDK7, in complex with TFIIH, activates RNA polymerase II for transcript elongation. Its consistent expression and activity contribute to DNA-bound peptide-mediated transcription and cellular growth regulation. CDK7&CCNH&MNAT1 Protein, Human (sf9, His) is the recombinant heterotrimer protein (consiting of CDK7, CCNH, MNAT1), expressed by Sf9 insect cells, with N-His labeled tag. CDK7&CCNH&MNAT1 Protein, Human (sf9, His), has molecular weight of ~25 & 38 & 44 kDa, respectively.

Cat. No.	Product Name	Application	Reactivity

HY-P80389

Cdk7 Antibody CDK7_HUMAN; Cyclin-dependent kinase 7; EC:2.7.11.22; EC:2.7.11.23; CDK7; CAK; CAK1; CDKN7; MO15; STK1; 39 kDa protein kinase (p39 Mo15); CDK-activating kinase 1; Cell division protein kinase 7; Serine/threonine-protein kinase 1; TFIIH basal transcription factor complex kinase subunit	WB；ELISA；IHC-P；IHC-F；ICC；IF	Human, Mouse, Rat
Cdk7 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 39 kDa, targeting to Cdk7. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks